48,830
edits
Difference between revisions of "ROS1-rearranged non-small cell lung carcinoma"
Jump to navigation
Jump to search
ROS1-rearranged non-small cell lung carcinoma (view source)
Revision as of 02:22, 31 December 2019
, 02:22, 31 December 2019→General
| Line 3: | Line 3: | ||
==General== | ==General== | ||
*ROS1-rearrangements are seen in approximately 1-2% of [[non-small cell carcinoma]].<ref name=pmid31720561>{{cite journal |vauthors=Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW |title=Targeted therapies for ROS1-rearranged non-small cell lung cancer |journal=Drugs Today |volume=55 |issue=10 |pages=641–652 |date=October 2019 |pmid=31720561 |doi=10.1358/dot.2019.55.10.3030646 |url=}}</ref> | *ROS1-rearrangements are seen in approximately 1-2% of [[non-small cell carcinoma]].<ref name=pmid31720561>{{cite journal |vauthors=Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW |title=Targeted therapies for ROS1-rearranged non-small cell lung cancer |journal=Drugs Today |volume=55 |issue=10 |pages=641–652 |date=October 2019 |pmid=31720561 |doi=10.1358/dot.2019.55.10.3030646 |url=}}</ref> | ||
*Respond to target therapy, e.g. [[crizotinib]].<ref name=pmid30980071>{{cite journal |vauthors=Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI |title=Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 |journal=Ann. Oncol. |volume=30 |issue=7 |pages=1121–1126 |date=July 2019 |pmid=30980071 |pmc=6637370 |doi=10.1093/annonc/mdz131 |url=}}</ref> | |||
==See also== | ==See also== | ||